This is the first of two phase-3 Pradaxa trials in the treatment of acute VTE; the other phase-3 trial in this indication is still recruiting and is expected to be completed in mid 2011: http://clinicaltrials.gov/ct2/show/study/NCT00680186 .
For the trial just presented at ASH, the top-line data were reported in August (#msg-43846491). The only problem I can see with the data is a relatively minor one:
Pradaxa seems to induce dyspepsia in some patients, which was noted in the phase-3 trial in AF (#msg-41018490). All told, Pradaxa appears to be a major advance relative to warfarin, and I doubt the concern mentioned above will impede the program to a material degree.
Note: Pradaxa is already approved in the EU for VTE prevention (#msg-27956748) and is reimbursed by NICE, which requires a strong benefit-cost tradeoff (#msg-32382343).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.